FIRST AMENDMENT TO SUBLEASE (Third Floor)Juno Therapeutics, Inc. • May 4th, 2017 • Biological products, (no disgnostic substances)
This First Amendment to the Sublease (this “First Amendment”) is effective as of this 15 , day of FEBRUARY , 2017, between Seattle Biomedical Research Institute, a Washington nonprofit corporation ("Sublandlord"), and Juno Therapeutics, Inc., a Delaware corporation (“Subtenant”) with reference to the following facts:
SECOND AMENDMENT TO SUBLEASEJuno Therapeutics, Inc. • May 4th, 2017 • Biological products, (no disgnostic substances)
This Second Amendment to the Sublease (this “Second Amendment”) is effective as of this 15 day of FEBRUARY , 2017, between Seattle Biomedical Research Institute, a Washington nonprofit corporation ("Sublandlord"), and Juno Therapeutics, Inc., a Delaware corporation (“Subtenant”) with reference to the following facts:
FIRST AMENDMENT TO SUBLEASE (Juno 2nd Floor; 307 WESTLAKE)Juno Therapeutics, Inc. • May 4th, 2017 • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made as of February 11, 2015 (the “Effective Date”), between Seattle Biomedical Research Institute, a Washington nonprofit corporation having a principal address at 307 Westlake Ave N., Suite 500, Seattle, WA 98109-5219 ("Sublandlord"), and Juno Therapeutics, Inc., a Delaware corporation having a principal address at 307 Westlake Avenue N., Suite 300, Seattle, WA 98109-5219 ("Subtenant").
